RxDoctor Payments Data

Nadia Zaki, MD

Neurology · Rochester Hills, MINPI 1184607616

Payments from drug & device makers

$26,317in general payments, 2019–2025

Across 1,382 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • UCB, Inc.$2K
  • Biogen$2K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Jazz Pharmaceuticals Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$690%
  • Food & beverage$22,93987%
  • Education$5752%
  • Gifts$2,73310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis137$4,315
UCB, Inc.123$1,823
Biogen103$1,723
AbbVie(2 entities)80$1,254
Teva Pharmaceuticals USA, Inc.80$1,248
Jazz Pharmaceuticals Inc.61$1,033
Neurocrine Biosciences, Inc.43$952
EMD Serono, Inc.59$951
Sanofi45$904
Amgen(2 entities)46$862
Bristol Myers Squibb56$836
SK Life Science, Inc.34$692
Johnson & Johnson43$665
Lundbeck LLC34$593
Lilly USA, LLC35$589
Harmony Biosciences LLC27$548
Eisai Inc.22$548
Pfizer28$428
Avanir Pharmaceuticals, Inc.24$427
Neurelis, Inc.17$355
Axsome Therapeutics, Inc.21$332
Greenwich Biosciences, Inc.10$310
Genentech USA, Inc.19$299
Vanda Pharmaceuticals Inc.11$277
AstraZeneca(2 entities)13$268
Argenx US, Inc.12$245
Acadia Pharmaceuticals Inc11$244
Otsuka America Pharmaceutical, Inc.11$223
Amneal Pharmaceuticals LLC10$218
Sumitomo Pharma America, Inc.11$214
Kyowa Kirin, Inc.10$205
Upsher-smith Laboratories LLC13$197
Biohaven Pharmaceuticals, Inc.9$183
E.r. Squibb & Sons, L.L.C.10$151
Adamas Pharmaceuticals, Inc.8$150
Takeda Pharmaceuticals U.S.A., Inc.7$149
Catalyst Pharmaceuticals, Inc.6$143
Supernus Pharmaceuticals, Inc.7$121
Scilex Pharmaceuticals Inc.6$115
Avadel CNS Pharmaceuticals, LLC5$108
TG Therapeutics, Inc.4$106
Corium, LLC7$103
Banner Life Sciences, LLC2$95
Aucta Pharmaceuticals, Inc.8$93
Acorda Therapeutics, Inc5$92
MDD US Operations, LLC5$90
Promius Pharma LLC5$74
Novo Nordisk1$71
Azurity Pharmaceuticals, Inc.3$54
Avion Pharmaceuticals3$51
Biohaven Pharmaceutical Holding Company Ltd.3$49
Medtronic(2 entities)2$48
Sanofi-aventis U.S. LLC2$40
GE HealthCare2$36
Sunovion Pharmaceuticals Inc.2$35
Mallinckrodt Enterprises LLC2$32
Merz Pharmaceuticals, LLC1$32
Resmed Corp2$32
Cycle Pharmaceuticals Inc1$31
Inspire Medical Systems, Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,317 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$137,760
Medicare patients
384
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate46$448,043
AustedoDeutetrabenazine19$218,617
IngrezzaValbenazine Tosylate21$205,394
CopaxoneGlatiramer Acetate26$149,197
EpidiolexCannabidiol (Cbd)19$93,451
QuliptaAtogepant46$55,816
Dimethyl Fumarate21$45,252
NourianzIstradefylline14$26,003
Lacosamide98$24,622
Ajovy AutoinjectorFremanezumab-Vfrm12$20,795
Dalfampridine ErDalfampridine27$19,928
AptiomEslicarbazepine Acetate13$15,462
Memantine Hcl ErMemantine Hcl156$14,123
Rivastigmine28$10,182
Memantine Hcl183$6,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,723$448,04346 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,248$367,81445 claims
Neurocrine Biosciences, Inc.Ingrezza$952$205,39421 claims
AbbVieQulipta$1,254$55,81646 claims
Kyowa Kirin, Inc.Nourianz$205$26,00314 claims
Sunovion Pharmaceuticals Inc.Aptiom$35$15,46213 claims
PfizerDilantin$428$3,76313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →